Evidence map›Paper›PMID 40858831›Full record

ArticleBritish journal of cancer2025

Aberrant PJA2-CHRM3 signaling creates a therapeutic vulnerability in gastric tumor.

Lingmeng Li, Jingyi Yin, Ling Zhang, Wenshuai Liu, Yinan Niu, Leihao Wang, Junjie Zhao, Yuan Gu, Zhaoming Wang, Dongli Liang and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Lingmeng Li *Key Laboratory of Systems Biomedicine (Ministry of Education) and Collaborative Innovation Center of Systems Biomedicine, Shanghai Center for Systems Biomedicine, Shanghai Jiao Tong University, Shanghai, China.
Jingyi Yin *Key Laboratory of Systems Biomedicine (Ministry of Education) and Collaborative Innovation Center of Systems Biomedicine, Shanghai Center for Systems Biomedicine, Shanghai Jiao Tong University, Shanghai, China.ORCID http://orcid.org/0009-0009-0349-3262
Ling ZhangKey Laboratory of Systems Biomedicine (Ministry of Education) and Collaborative Innovation Center of Systems Biomedicine, Shanghai Center for Systems Biomedicine, Shanghai Jiao Tong University, Shanghai, China.
Wenshuai LiuDepartment of Gastrointestinal Surgery, Gastric cancer center, Zhongshan Hospital, Fudan University, Shanghai, China.
Yinan NiuKey Laboratory of Systems Biomedicine (Ministry of Education) and Collaborative Innovation Center of Systems Biomedicine, Shanghai Center for Systems Biomedicine, Shanghai Jiao Tong University, Shanghai, China.
Leihao WangDepartment of Gastrointestinal Surgery, Gastric cancer center, Zhongshan Hospital, Fudan University, Shanghai, China.
Junjie ZhaoDepartment of Gastrointestinal Surgery, Gastric cancer center, Zhongshan Hospital, Fudan University, Shanghai, China.
Yuan GuDepartment of Gastrointestinal Surgery, Gastric cancer center, Zhongshan Hospital, Fudan University, Shanghai, China.
Zhaoming WangDepartment of Gastrointestinal Surgery, Gastric cancer center, Zhongshan Hospital, Fudan University, Shanghai, China.
Dongli LiangLaboratory animal center, Instrumental analysis center, Shanghai Jiao Tong University, Shanghai, China.
Guoxiang FuD1 Medical Technology Company, Nanxiang Precision Medicine Industrial Park, Shanghai, China.
Guoqiang HuaD1 Medical Technology Company, Nanxiang Precision Medicine Industrial Park, Shanghai, China.
Xuefei WangDepartment of Gastrointestinal Surgery, Gastric cancer center, Zhongshan Hospital, Fudan University, Shanghai, China.ORCID http://orcid.org/0000-0002-2645-0953
Liyu HuangKey Laboratory of Systems Biomedicine (Ministry of Education) and Collaborative Innovation Center of Systems Biomedicine, Shanghai Center for Systems Biomedicine, Shanghai Jiao Tong University, Shanghai, China. huangly@sjtu.edu.cn.ORCID http://orcid.org/0000-0003-1192-3698

Funding

National Natural Science Foundation of China (National Science Foundation of China) 82472666
6 · The paper itself

Abstract

backgroundVagal innervation plays a pivotal role in gastric tumorigenesis and tumor progression. However, the upstream signaling regulating acetylcholine receptors (AChRs) and its contribution to carcinogenesis remains largely elusive.

methodsWe constructed Trp53

resultsmAChR inhibitors were identified as the most effective at suppressing Trp53

conclusionsThis previously unknown PJA2-CHRM3 signaling axis provides further understanding of cholinergic innervation as well as identifies a new therapeutic vulnerability in DGC.

Indexed as

Receptor, Muscarinic M3Stomach NeoplasmsAnimalsCadherinsCell Line, TumorHumansMiceOrganoidsSignal TransductionTumor Suppressor Protein p53CadherinsCHRM3 protein, humanReceptor, Muscarinic M3Tumor Suppressor Protein p53

Identifiers

PMID40858831
PMCPMC12533036

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.